Caris brings precision medicine assays closer to market

By The Science Advisory Board staff writers

April 28, 2020 -- Caris Life Sciences has submitted premarket approval (PMA) applications to the U.S. Food and Drug Administration (FDA) for its MI Exome CDx and MI Transcriptome CDx assays.

MI Exome CDx for whole-exome sequencing (DNA) and MI Transcriptome CDx for whole transcriptome sequencing (RNA) are precision-medicine assays that include key companion diagnostic biomarkers with therapy claims. The assays detect all classes of alterations, including genomic signatures for microsatellite instability (MSI), tumor mutational burden (TMB), and loss of heterozygosity (LOH), according to the company.

A sequencing-based test utilizing DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens, MI Exome CDx provides qualitative detection of genomic alterations. MI Transcriptome CDx, which received a breakthrough device designation by the FDA in 2019, is a sequencing-based test that utilizes RNA isolated from FFPE tumor tissue specimens to qualitatively detect genomic and transcriptomic alterations, Caris said.

Indivumed, Personalis partner on personalized oncology therapies
Indivumed and Personalis are joining forces in a collaboration aimed at enabling personalized oncology treatments.
Artificial intelligence helps researchers find new antibiotics
To address antibiotic resistance, researchers have developed a machine-learning approach that can search millions of known chemicals to find new...
Leveraging new technologies to push the boundaries of our knowledge of cell biology
At the American Society of Cell Biology, European Molecular Biology Organization Joint Meeting in Washington, DC from December 7-11, emerging topics and...
Data Science Vital to Large-Scale Cellular Studies
Data science as a discipline has become a central aspect of many commercial endeavors. A large range of distinct applications have adopted its approaches...
New genetic risk factor discovered for Alzheimer's disease
A new genetic risk factor for late-onset Alzheimer's disease (LOAD) has been identified by researchers from the University of Kentucky. The results of...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
BioProcess International Europe
July 13-17
Central European Time Zone (CET) Netherlands
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter